Palatin Technologies INC 8-K filings

Palatin Technologies, Inc. announced the results of its annual meeting, with shareholders overwhelmingly approving director elections, auditor ratification, and amendments to the stock incentive plan.

Palatin Technologies, Inc. will voluntarily transfer its stock exchange listing from the NYSE American to the Nasdaq Capital Market effective May 29, 2026.

Palatin Technologies, Inc. announced its decision to hold annual non-binding advisory votes on executive compensation following stockholder approval at its 2025 Annual Meeting.

Palatin Technologies announced the closing of its $18.2 million public offering, including the full exercise of the over-allotment option, and regained NYSE American listing compliance.

Palatin Technologies announced a $15.8 million public offering and expects to resume trading on the NYSE American exchange, driven by a recent collaboration and capital raise.

Palatin Technologies announced a $6.5 million milestone payment from its collaboration with Boehringer Ingelheim for a retinal disease treatment.

Palatin Technologies, Inc. common stock began trading on the OTCQB Market under the symbol PTNT following its delisting from NYSE American and a reverse stock split.

Palatin Technologies has entered a global research collaboration and licensing agreement with Boehringer Ingelheim for melanocortin receptor-targeted peptides to treat retinal diseases, including diabetic retinopathy.

Palatin Technologies, Inc. announced revised dates for its 1-for-50 reverse stock split, now effective August 11, 2025, due to FINRA approval delays.

Palatin Technologies, Inc. will implement a 1-for-50 reverse stock split effective August 8, 2025, to address its low share price and NYSE American listing compliance issues.

Palatin Technologies, Inc. stockholders approved a reverse stock split, director elections, and warrant exercises at their annual meeting, following the company's delisting from NYSE American due to low stock price.

Palatin Technologies, Inc. has received final notification of delisting from NYSE American due to low stock price, but intends to appeal the decision.

Palatin Technologies, Inc. has completed a private placement of convertible preferred stock and warrants, raising $340,000, following its delisting from the NYSE American due to low stock price.

Palatin Technologies prices a public offering for $11.5 million while facing delisting from the NYSE American.

Palatin Technologies receives notification from NYSE American regarding delisting proceedings due to non-compliance with continued listing standards and intends to appeal the decision.

Palatin Technologies reports positive topline results from Phase 2 studies of PL8177 for ulcerative colitis and bremelanotide with tirzepatide for obesity.

Palatin Technologies has entered into an agreement with A.G.P./Alliance Global Partners to sell up to $6 million of its common stock through an at-the-market offering.

Palatin Technologies secures $4.7 million through a registered direct offering and concurrent private placement to bolster working capital.

Palatin Technologies has entered into an agreement with an institutional investor, resulting in the exercise of existing warrants for $3.4 million and the issuance of new Series C and D warrants.

Palatin Technologies reported its first quarter fiscal year 2025 results, highlighting a strategic shift towards obesity programs and exploring options for non-obesity assets.

Palatin Technologies has received a notice from NYSE American for not meeting continued listing standards due to insufficient stockholders' equity.

Palatin Technologies reported its fiscal year 2024 financial results and provided updates on its clinical programs, including progress in obesity, dry eye disease, and male sexual dysfunction.

Palatin Technologies has announced the date for its annual stockholders meeting, along with deadlines for shareholder proposals and director nominations.

Palatin Technologies held its annual meeting on June 27, 2024, where stockholders elected directors, ratified the accounting firm, approved a stock plan amendment, and advised on executive compensation.

Palatin Technologies has entered into a warrant inducement agreement, resulting in the exercise of existing warrants for approximately $6.1 million in gross proceeds and the issuance of new warrants.

Palatin Technologies reports positive results from its Phase 3 MELODY-1 trial for dry eye disease, along with updates on other clinical programs and financial results for the third quarter of fiscal year 2024.

Palatin Technologies reported its second quarter fiscal year 2024 financial results, highlighted by the completion of the Vyleesi asset sale and progress in its melanocortin receptor pipeline.

Palatin Technologies has successfully raised $10 million through a registered direct offering of common stock and private placement of warrants.